Drugs that potentially could purge the body of so-called senescent cells — thought to play a role in aging — helped Peninsula company snare a $116 million Series B round from a wide range of investors, including Amazon founder and CEO Jeff Bezos' investment arm.
Unity Biotechnology, which also named biotech veteran Keith Leonard as CEO, plans to use the cash to take its drugs to prevent, halt or reverse diseases of aging into the clinic over the next 12 to 18 months. Its lead programs are in…
Drugs that potentially could purge the body of so-called senescent cells — thought to play a role in aging — helped Peninsula company snare a $116 million Series B round from a wide range of investors, including Amazon founder and CEO Jeff Bezos' investment arm.
Unity Biotechnology, which also named biotech veteran Keith Leonard as CEO, plans to use the cash to take its drugs to prevent, halt or reverse diseases of aging into the clinic over the next 12 to 18 months. Its lead programs are in…